Glycine Transporter Inhibitors as a Potential Therapeutic Strategy for Chronic Pain with Memory Impairment
- 1 May 2008
- journal article
- abstracts
- Published by Ovid Technologies (Wolters Kluwer Health) in Anesthesiology
- Vol. 108 (5), 929-937
- https://doi.org/10.1097/aln.0b013e31816c9044
Abstract
Background Impaired excitatory and inhibitory balance in the spinal dorsal horn has a crucial role in the pathophysiology of chronic pain. The authors addressed the therapeutic impact of increasing spinal glycine applied exogenously or via blockade of glycine transporter 1 using its selective inhibitors sarcosine and N-[3-(4'-fluorophenyl)-3-(4'-phenylphenoxy)propyl]sarcosine on neuropathic and inflammatory pain in mice. Methods Mice with thermal and mechanical hypersensitivity after partial ligation of the sciatic nerve (Seltzer model) or mice with mechanical hypersensitivity after streptozotocin injection received intrathecal injection of glycine, sarcosine, and N-[3-(4'-fluorophenyl)-3-(4'-phenylphenoxy)propyl]sarcosine. These drugs were also intrathecally injected in mice to assess their effects on formalin-evoked nociceptive behaviors. The supraspinal effect of blockade of glycine transporter 1 was studied on tetanus-induced long-term potentiation of the Schaffer-collateral synapses in hippocampal slices prepared from Seltzer model mice. Results Glycine, sarcosine, and N-[3-(4'-fluorophenyl)-3-(4'-phenylphenoxy)propyl]sarcosine ameliorated thermal and mechanical hypersensitivity in Seltzer model mice, and reduced mechanical hypersensitivity in streptozotocin-injected diabetic mice. Moreover, they selectively inhibited the second phase of formalin-evoked licking/biting behavior. In hippocampal slices prepared from Seltzer model mice, long-term potentiation was maintained at a significantly lower level than that in sham-treated mice. Such impairment of long-term potentiation was never observed when it was induced in the presence of N-[3-(4'-fluorophenyl)-3-(4'-phenylphenoxy)propyl]sarcosine. Conclusions An increase in endogenous glycine via glycine transporter 1 blockade not only results in a net inhibitory influence on pain transmission at the spinal level but also supraspinally relieves decreased synaptic efficacy presumably related to cognitive disturbance often described in patients with chronic pain.Keywords
This publication has 45 references indexed in Scilit:
- Glycine transporters: crucial roles of pharmacological interest revealed by gene deletionTrends in Pharmacological Sciences, 2005
- Peripheral nerve injury induces trans‐synaptic modification of channels, receptors and signal pathways in rat dorsal spinal cordEuropean Journal of Neuroscience, 2004
- Central sensitization and LTP: do pain and memory share similar mechanisms?Trends in Neurosciences, 2003
- Reduction of glycine receptor-mediated miniature inhibitory postsynaptic currents in rat spinal lamina I neurons after peripheral inflammationNeuroscience, 2003
- Partial Peripheral Nerve Injury Promotes a Selective Loss of GABAergic Inhibition in the Superficial Dorsal Horn of the Spinal CordJournal of Neuroscience, 2002
- Learning and memory in pain pathwaysPain, 2000
- Neuronal Plasticity: Increasing the Gain in PainScience, 2000
- Long-term intrathecal administration of glycine prevents mechanical hyperalgesia in a rat model of neuropathic painNeurological Research, 2000
- Characterization of spinal amino acid release and touch-evoked allodynia produced by spinal glycine or GABAA receptor antagonistNeuroscience, 1999
- The contribution of GABAA and glycine receptors to central sensitization: disinhibition and touch-evoked allodynia in the spinal cordJournal of Neurophysiology, 1994